KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Cost of Revenue (2016 - 2025)

Teva Pharmaceutical Industries' Cost of Revenue history spans 10 years, with the latest figure at $753.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue fell 88.57% year-over-year to $753.0 million, compared with a TTM value of $5.6 billion through Dec 2025, down 33.67%, and an annual FY2025 reading of $2.7 billion, down 68.33% over the prior year.
  • Cost of Revenue for Q4 2025 was $753.0 million at Teva Pharmaceutical Industries, down from $2.2 billion in the prior quarter.
  • The five-year high for Cost of Revenue was $6.6 billion in Q4 2024, with the low at $539.0 million in Q3 2022.
  • Average Cost of Revenue over 5 years is $1.3 billion, with a median of $624.0 million recorded in 2024.
  • Year-over-year, Cost of Revenue surged 980.33% in 2024 and then tumbled 88.57% in 2025.
  • Tracing TEVA's Cost of Revenue over 5 years: stood at $2.1 billion in 2021, then plummeted by 73.22% to $549.0 million in 2022, then increased by 11.11% to $610.0 million in 2023, then surged by 980.33% to $6.6 billion in 2024, then crashed by 88.57% to $753.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Cost of Revenue are $753.0 million (Q4 2025), $2.2 billion (Q3 2025), and $2.1 billion (Q2 2025).